- Home
- IMMR vs GALT Comparison
IMMR vs GALT Comparison
Compare IMMR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMR
- GALT
- Stock Information
- Founded
- IMMR 1993
- GALT 2000
- Country
- IMMR United States
- GALT United States
- Employees
- IMMR N/A
- GALT N/A
- Industry
- IMMR Computer peripheral equipment
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- IMMR Technology
- GALT Health Care
- Exchange
- IMMR Nasdaq
- GALT Nasdaq
- Market Cap
- IMMR 229.4M
- GALT 232.3M
- IPO Year
- IMMR 1999
- GALT N/A
- Fundamental
- Price
- IMMR $6.39
- GALT $5.55
- Analyst Decision
- IMMR Strong Buy
- GALT Strong Buy
- Analyst Count
- IMMR 2
- GALT 3
- Target Price
- IMMR $12.25
- GALT $6.00
- AVG Volume (30 Days)
- IMMR 389.2K
- GALT 407.7K
- Earning Date
- IMMR 12-15-2025
- GALT 11-14-2025
- Dividend Yield
- IMMR 2.81%
- GALT N/A
- EPS Growth
- IMMR 57.07
- GALT N/A
- EPS
- IMMR 2.04
- GALT N/A
- Revenue
- IMMR $163,133,000.00
- GALT N/A
- Revenue This Year
- IMMR $988.71
- GALT N/A
- Revenue Next Year
- IMMR $109.72
- GALT N/A
- P/E Ratio
- IMMR $3.14
- GALT N/A
- Revenue Growth
- IMMR 338.21
- GALT N/A
- 52 Week Low
- IMMR $6.32
- GALT $0.73
- 52 Week High
- IMMR $10.72
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- IMMR 34.77
- GALT 55.39
- Support Level
- IMMR $6.75
- GALT $5.15
- Resistance Level
- IMMR $7.00
- GALT $6.15
- Average True Range (ATR)
- IMMR 0.20
- GALT 0.49
- MACD
- IMMR -0.02
- GALT -0.02
- Stochastic Oscillator
- IMMR 13.97
- GALT 38.84
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.